Literature DB >> 18627476

Successful treatment for chromoblastomycosis caused by Fonsecaea monophora: a report of three cases in Guangdong, China.

Junmin Zhang1, Liyan Xi, Changming Lu, Xiqing Li, Ting Xie, Hui Zhang, Zhi Xie, Sybren De Hoog.   

Abstract

Fonsecaea pedrosoi is the most prevalent aetiological agent of chromoblastomycosis. Fonsecaea monophora is a new species segregated from Fonsecaea pedrosoi. Herein, we report on three cases of chromoblastomycosis caused by F. monophora that were successfully treated with terbinafine and/or itraconazole. Clinical characteristics and mycological parameters are described. Two of the three patients underwent combination therapy with itraconazole and terbinafine during early stages of treatment and were completely healed in a relatively short course of treatment.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18627476     DOI： 10.1111/j.1439-0507.2008.01547.x

Source DB:  PubMed          Journal:  Mycoses        ISSN： 0933-7407            Impact factor:   4.377


  14 in total

1.  Photodynamic therapy combined with terbinafine against chromoblastomycosis and the effect of PDT on Fonsecaea monophora in vitro.

Authors:  Yongxuan Hu; Xiaowen Huang; Sha Lu; Michael R Hamblin; Eleftherios Mylonakis; Junmin Zhang; Liyan Xi
Journal:  Mycopathologia       Date:  2014-11-01       Impact factor: 2.574

2.  Sixty-year-old man with slowly expanding nodular plaque on the thigh.

Authors:  Peggy A Wu; Maria L Turner; Edward W Cowen; Eleanor Wilson; Yvonne R Shea; Timothy Jancel; Alexandra F Freeman
Journal:  J Am Acad Dermatol       Date:  2010-12       Impact factor: 11.527

3.  In vitro evaluation of the type of interaction obtained by the combination of terbinafine and itraconazole, voriconazole, or amphotericin B against dematiaceous molds.

Authors:  Fernanda Simas Corrêa Biancalana; Luzia Lyra; Angélica Zaninelli Schreiber
Journal:  Antimicrob Agents Chemother       Date:  2011-06-20       Impact factor: 5.191

4.  Molecular cloning, characterization and differential expression of Cdc42 in Fonsecaea monophora.

Authors:  Zhi Xie; Peiying Feng; Junming Zhang; Xiqing Li; Jiufeng Sun; Changming Lu; Huaiqiu Huang; Liyan Xi
Journal:  Mol Biol Rep       Date:  2011-05-15       Impact factor: 2.316

5.  Chromoblastomycosis due to Fonsecaea monophora in a man with nephritic syndrome.

Authors:  Huan Tan; Yan Xu; Xue-Mei Lan; Ya-Guang Wu; Cun-Jian Zhou; Xi-Chuan Yang
Journal:  Mycopathologia       Date:  2015-01-10       Impact factor: 2.574

6.  Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.

Authors:  Enrique Calvo; F Javier Pastor; M Mar Rodríguez; Emilio Mayayo; Valentina Salas; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

7.  In vitro susceptibility of environmental isolates of Exophiala dermatitidis to five antifungal drugs.

Authors:  Ana Paula Miranda Duarte; Fernando Carlos Pagnocca; Noemi Carla Baron; Marcia de Souza Carvalho Melhem; Gislene Aparecida Palmeira; Dejanira de Franceschi de Angelis; Derlene Attili-Angelis
Journal:  Mycopathologia       Date:  2012-11-16       Impact factor: 2.574

8.  Chromoblastomycosis due to Fonsecaea pedrosoi and F. monophora in Cuba.

Authors:  Hamid Badali; Maydelin Fernández-González; Bita Mousavi; Maria Teresa Illnait-Zaragozi; Juan Carlos González-Rodríguez; G Sybren de Hoog; Jacques F Meis
Journal:  Mycopathologia       Date:  2013-03-08       Impact factor: 2.574

9.  A case of relapsed chromoblastomycosis due to Fonsecaea monophora: antifungal susceptibility and phylogenetic analysis.

Authors:  Tatiane Caroline Daboit; Cibele Massotti Magagnin; Daiane Heidrich; Mauricio Ramírez Castrillón; Sandra Denise Camargo Mendes; Gerson Vettorato; Patrícia Valente; Maria Lúcia Scroferneker
Journal:  Mycopathologia       Date:  2013-05-04       Impact factor: 2.574

Review 10.  Chromoblastomycosis in Mainland China: a systematic review on clinical characteristics.

Authors:  Sha Lu; Changming Lu; Junmin Zhang; Yongxuan Hu; Xiqing Li; Liyan Xi
Journal:  Mycopathologia       Date:  2012-10-20       Impact factor: 2.574
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.